Literature DB >> 11111186

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

B J Schmitz-Dräger1, P J Goebell, T Ebert, Y Fradet.   

Abstract

OBJECTIVES: Anomalies of the p53 tumor suppressor gene have been reported for a variety of different tumor types. Also in urothelial cancer accumulation of the P53 protein has been linked with an unfavorable prognosis of the patients. Despite the growing number of publications confusion remains because key questions regarding p53 accumulation in bladder cancer are still unanswered. The objective of this manuscript was to review all published literature on the association of p53 accumulation and prognosis of patients with bladder cancer. Furthermore, putative reasons for the conflicting results should be defined as a basis for future research.
METHODS: The entry criteria for the analysis were met by 43 trials comprising 3,764 patients out of 138 publications found through Medline search.
RESULTS: Comparison between the trials yielded considerable differences obviously due to technical aspects, e.g. the selection of the antibody and the use of different cut-off values, study design and patient selection.
CONCLUSIONS: From this analysis it becomes evident that further retrospective investigations will not contribute to the solution of the problem and thus are obsolete. There is an obvious need for standardization of the assay procedure and the assessment of the specimens as well as for the initiation of a prospective multicenter trial to provide definite answers.

Entities:  

Mesh:

Year:  2000        PMID: 11111186     DOI: 10.1159/000020364

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  22 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 2.  Landmarks in non-muscle-invasive bladder cancer.

Authors:  Laura S Mertens; Yann Neuzillet; Simon Horenblas; Bas W G van Rhijn
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

Review 3.  A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck.

Authors:  Sankalap Tandon; Catrin Tudur-Smith; Richard D Riley; Mark T Boyd; Terence M Jones
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

Review 4.  [Value of biomarkers in urology].

Authors:  P J Goebell; B Keck; S Wach; B Wullich
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

5.  Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients.

Authors:  Rania Bakry; Mohamed I El-Sayed; Hesham M Hamza; Khaled H Hassan
Journal:  Oncol Lett       Date:  2015-11-17       Impact factor: 2.967

6.  P27(Kip1) and Ki-67 expression analysis in transitional cell carcinoma of the bladder.

Authors:  Bartosz Dybowski; Jolanta Kupryjańczyk; Alina Rembiszewska; Roman Pykało; Andrzej Borkowski
Journal:  Urol Res       Date:  2003-09-27

7.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

Review 8.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

9.  The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.

Authors:  M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 10.  [Urinary cytology in cases of bladder cancer: a critical evaluation].

Authors:  P Rathert
Journal:  Urologe A       Date:  2003-03-26       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.